Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 1109

1.

Prognostic value of ERCC1, thymidylate synthase, and glutathione S-transferase pi for 5-FU/oxaliplatin chemotherapy in advanced colorectal cancer.

Kim SH, Kwon HC, Oh SY, Lee DM, Lee S, Lee JH, Roh MS, Kim DC, Park KJ, Choi HJ, Kim HJ.

Am J Clin Oncol. 2009 Feb;32(1):38-43. doi: 10.1097/COC.0b013e31817be58e.

PMID:
19194123
2.
3.

Predictive value of expression of ERCC 1 and GST-p for 5-fluorouracil/oxaliplatin chemotherapy in advanced colorectal cancer.

Noda E, Maeda K, Inoue T, Fukunaga S, Nagahara H, Shibutani M, Amano R, Nakata B, Tanaka H, Muguruma K, Yamada N, Yashiro M, Ohira M, Ishikawa T, Hirakawa K.

Hepatogastroenterology. 2012 Jan-Feb;59(113):130-3. doi: 10.5754/hge11022.

PMID:
21940361
4.

Messenger RNA expression of TS and ERCC1 in colorectal cancer and matched liver metastasis.

Kobayashi H, Sugihara K, Uetake H, Higuchi T, Yasuno M, Enomoto M, Iida S, Azuma M, Mori R, Omori A, Lenz HJ, Danenberg KD, Danenberg PV.

Int J Oncol. 2008 Dec;33(6):1257-62.

PMID:
19020759
5.

Predictive value of thymidylate synthase expression in resected metastases of colorectal cancer.

Corsi DC, Ciaparrone M, Zannoni G, Mancini M, Cassano A, Specchia M, Pozzo C, Martini M, Barone C.

Eur J Cancer. 2002 Mar;38(4):527-34.

PMID:
11872345
6.

Predictive role of thymidylate synthase, dihydropyrimidine dehydrogenase and thymidine phosphorylase expression in colorectal cancer patients receiving adjuvant 5-fluorouracil.

Ciaparrone M, Quirino M, Schinzari G, Zannoni G, Corsi DC, Vecchio FM, Cassano A, La Torre G, Barone C.

Oncology. 2006;70(5):366-77. Epub 2006 Dec 15.

PMID:
17179731
7.

Prognostic value of p53, glutathione S-transferase pi, and thymidylate synthase for neoadjuvant cisplatin-based chemotherapy in head and neck cancer.

Shiga H, Heath EI, Rasmussen AA, Trock B, Johnston PG, Forastiere AA, Langmacher M, Baylor A, Lee M, Cullen KJ.

Clin Cancer Res. 1999 Dec;5(12):4097-104.

8.

Clinicopathologic significance of ERCC1, thymidylate synthase and glutathione S-transferase P1 expression for advanced gastric cancer patients receiving adjuvant 5-FU and cisplatin chemotherapy.

Kim KH, Kwon HC, Oh SY, Kim SH, Lee S, Kwon KA, Jang JS, Kim MC, Kim SJ, Kim HJ.

Biomarkers. 2011 Feb;16(1):74-82. doi: 10.3109/1354750X.2010.533284. Epub 2010 Dec 6.

PMID:
21133646
9.

[The expression of thymidylate synthase (TS) and excision repair complementing-1 (ERCC-1) protein in patients with unresectable colorectal cancer treated with mFOLFOX6 therapy].

Ishibashi K, Okada N, Ishiguro T, Kuwabara K, Ohsawa T, Yokoyama M, Kumamoto K, Haga N, Mori T, Yamada H, Miura I, Tamaru J, Itoyama S, Ishida H.

Gan To Kagaku Ryoho. 2010 Nov;37(12):2532-5. Japanese.

PMID:
21224630
10.

ERCC1 codon 118 polymorphism is a predictive factor for the tumor response to oxaliplatin/5-fluorouracil combination chemotherapy in patients with advanced colorectal cancer.

Viguier J, Boige V, Miquel C, Pocard M, Giraudeau B, Sabourin JC, Ducreux M, Sarasin A, Praz F.

Clin Cancer Res. 2005 Sep 1;11(17):6212-7.

11.

ERCC1 predicting chemoradiation resistance and poor outcome in oesophageal cancer.

Kim MK, Cho KJ, Kwon GY, Park SI, Kim YH, Kim JH, Song HY, Shin JH, Jung HY, Lee GH, Choi KD, Kim SB.

Eur J Cancer. 2008 Jan;44(1):54-60. Epub 2007 Oct 31.

PMID:
17976974
12.

ERCC1 and thymidylate synthase mRNA levels predict survival for colorectal cancer patients receiving combination oxaliplatin and fluorouracil chemotherapy.

Shirota Y, Stoehlmacher J, Brabender J, Xiong YP, Uetake H, Danenberg KD, Groshen S, Tsao-Wei DD, Danenberg PV, Lenz HJ.

J Clin Oncol. 2001 Dec 1;19(23):4298-304.

PMID:
11731512
13.

ERCC1 mRNA levels and survival of advanced gastric cancer patients treated with a modified FOLFOX regimen.

Wei J, Zou Z, Qian X, Ding Y, Xie L, Sanchez JJ, Zhao Y, Feng J, Ling Y, Liu Y, Yu L, Rosell R, Liu B.

Br J Cancer. 2008 Apr 22;98(8):1398-402. doi: 10.1038/sj.bjc.6604317. Epub 2008 Mar 25.

14.

High gene expression of TS1, GSTP1, and ERCC1 are risk factors for survival in patients treated with trimodality therapy for esophageal cancer.

Joshi MB, Shirota Y, Danenberg KD, Conlon DH, Salonga DS, Herndon JE 2nd, Danenberg PV, Harpole DH Jr.

Clin Cancer Res. 2005 Mar 15;11(6):2215-21.

15.

Relationship between TYMS and ERCC1 mRNA expression and in vitro chemosensitivity in colorectal cancer.

Cho YB, Chung HJ, Lee WY, Choi SH, Kim HC, Yun SH, Chun HK.

Anticancer Res. 2011 Nov;31(11):3843-9.

PMID:
22110208
16.

Oxaliplatin, 5-fluorouracil, and leucovorin as second-line treatment for advanced pancreatic cancer.

Novarino A, Satolli MA, Chiappino I, Giacobino A, Bellone G, Rahimi F, Milanesi E, Bertetto O, Ciuffreda L.

Am J Clin Oncol. 2009 Feb;32(1):44-8. doi: 10.1097/COC.0b013e31817be5a9.

PMID:
19194124
17.

Improving the clinical risk score: an analysis of molecular biomarkers in the era of modern chemotherapy for resectable hepatic colorectal cancer metastases.

Maithel SK, Gönen M, Ito H, Dematteo RP, Allen PJ, Fong Y, Blumgart LH, Jarnagin WR, D'Angelica MI.

Surgery. 2012 Feb;151(2):162-70. doi: 10.1016/j.surg.2011.07.020. Epub 2011 Oct 6.

PMID:
21982065
18.

Modified FOLFOX-6 chemotherapy in advanced gastric cancer: Results of phase II study and comprehensive analysis of polymorphisms as a predictive and prognostic marker.

Keam B, Im SA, Han SW, Ham HS, Kim MA, Oh DY, Lee SH, Kim JH, Kim DW, Kim TY, Heo DS, Kim WH, Bang YJ.

BMC Cancer. 2008 May 27;8:148. doi: 10.1186/1471-2407-8-148.

19.

Pharmacogenetic profiling in patients with advanced colorectal cancer treated with first-line FOLFOX-4 chemotherapy.

Ruzzo A, Graziano F, Loupakis F, Rulli E, Canestrari E, Santini D, Catalano V, Ficarelli R, Maltese P, Bisonni R, Masi G, Schiavon G, Giordani P, Giustini L, Falcone A, Tonini G, Silva R, Mattioli R, Floriani I, Magnani M.

J Clin Oncol. 2007 Apr 1;25(10):1247-54. Erratum in: J Clin Oncol. 2009 Jul 1;27(19):3262.

PMID:
17401013
20.

Downregulation of TS, DPD, ERCC1, GST-Pi, EGFR, and HER2 gene expression after neoadjuvant three-modality treatment in patients with esophageal cancer.

Schneider S, Uchida K, Brabender J, Baldus SE, Yochim J, Danenberg KD, Salonga D, Chen P, Tsao-Wei D, Groshen S, Hoelscher AH, Schneider PM, Danenberg PV.

J Am Coll Surg. 2005 Mar;200(3):336-44.

PMID:
15737843

Supplemental Content

Support Center